Show simple item record

A Statistical Profile of Pharmaceutical Industry Liability, 1976-1989

dc.contributor.authorViscusi, W. Kip
dc.contributor.authorMoore, Michael J., 1953-
dc.contributor.authorAlbright, James
dc.date.accessioned2013-12-14T00:37:00Z
dc.date.available2013-12-14T00:37:00Z
dc.date.issued1994
dc.identifier.citation24 Seton Hall L. Rev. 1418 (1994)en_US
dc.identifier.urihttp://hdl.handle.net/1803/5817
dc.description.abstractThere is little question that the imposition of constraints on awards and other pro-defendant changes in the liability regime will reduce liability costs. However, the patterns observed in the federal courts are quite pronounced, far beyond what even the most ardent proponent of liability reform may have expected. Recent research analyzing the specific effect of liability reforms on general liability insurance and medical malpractice insurance suggests that these measures did have a significant role in limiting liability costs. 18 Damage cap reforms appear to have been particularly influential. However, the effect on liability insurance costs is not as dramatic as the stark shifts in Federal litigation patterns in the late 1980s, which suggest that other aspects of the liability regime may be influential as well.en_US
dc.format.extent1 document (20 pages)en_US
dc.format.mimetypeapplication/pdf
dc.language.isoen_USen_US
dc.publisherSeton Hall Law Reviewen_US
dc.subject.lcshTort liability of corporations -- United Statesen_US
dc.subject.lcshPharmaceutical industry -- United Statesen_US
dc.subject.lcshLaw reform -- United Statesen_US
dc.subject.lcshLiability (Law) -- United Statesen_US
dc.titleA Statistical Profile of Pharmaceutical Industry Liability, 1976-1989en_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record